

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV485023535US

Express Mail Label Number

September 7, 2004

Date of Deposit

Form PTO-1390-MOD (REV 10-96)		U. S. Department of Commerce Patent and Trademark Office		ATTORNEY'S DOCKET NUMBER PA/4-32394A	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Not Yet Assigned	
				<b>10/506 821</b>	
INTERNATIONAL APPLICATION NO. PCT/EP03/02322		INTERNATIONAL FILING DATE 6 March 2003 (06.03.03)		PRIORITY DATE CLAIMED 7 March 2002 (07.03.02)	
TITLE OF INVENTION SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING LUMIRACOXIB					
APPLICANT(S) FOR DO/EO/US KARNACHI ET AL.					

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau. (See Form PCT/IB/308)
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern document(s) or information included.**

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Application Data Sheet and Post Card.

**Not Yet Assigned**

PCT/EP03/02322

PA/4-32394A

**CALCULATIONS** PTO USE ONLY

**BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):**

**\$920**

**\$730**

**\$770**

**\$1.080**

**\$100**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 920

9

\$ 198

\$

<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$ 1204</b>
--------------------------------------	--	----------------

9

<b>SUBTOTAL =</b>	<b>\$ 1204</b>
-------------------	----------------

Φ

<b>TOTAL NATIONAL FEE =</b>	<b>\$ 1204</b>
-----------------------------	----------------

9

<b>TOTAL FEES ENCLOSED =</b>	<b>\$ 1204</b>
------------------------------	----------------

Amount to be:

refunded

charged

- a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1204 to cover the above fees. A duplicate copy of this form is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

Send all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie  
Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080

Edward J. Wilusz, Jr.  
Attorney for Applicants  
Reg. No. 52,370  
(862) 778-7960